GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
PHILADELPHIA and OXFORD, United Kingdom, March 02, 2016 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present at Cowen and Company’s 36th Annual Health Care Conference on Monday, March 7th at 4:40 PM (9:40 PM GMT). The conference is being held at the Boston Marriott Copley Place, in Boston, MA.
Adaptimmune’s presentation will be webcast live for investors through the investor section of www.adaptimmune.com and available for a period of 30 days following the conference.
About Adaptimmune
Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor (TCR) platform. Established in 2008, the company aims to utilize the body’s own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is an affinity enhanced T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO TCR affinity enhanced T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. Adaptimmune has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. In addition, Adaptimmune has a number of proprietary programs. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 200 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com.
Adaptimmune Contacts Will Roberts Vice President, Investor Relations T: (215) 825-9306 E: [email protected] Margaret Henry Head of PR T: +44 (0)1235 430036 Mob: +44 (0)7710 304249 E: [email protected]
